Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM333 in Relapsed or Refractory Acute Myeloid Leukemia
NCT03516760Phase 1Terminated
- Sponsor
- AvenCell Therapeutics
- Start
- Apr 2018
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GEM333 in acute myeloid leukemia (AML), sponsored by AvenCell Therapeutics. Primary endpoints: Maximum Tolerated Dose, Incidence of Dose Limiting Toxicity and 1 more. Started Apr 2018; status: terminated.
02
Drugs
GEM333
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03516760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516760.